See More Hear More Watch More Hear More Get on iTunes
Roll Call RollCall

BioSimilar Drugs Nearing Approval

A Food and Drug Administration advisory panel unanimously recommended the approval of the first biosimilar or copycat drug product. If the drug is approved it will likely be followed by other biosimilar drugs, which reportedly could save $250 billion in health costs over the next decade.


More from